1st Quarter - Report

TCH GROUP, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Animals ANI

Education and awareness regarding illegal compounding of veterinary drugs for animals.

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Issues related to the Medicaid rebate policy; coverage and reimbursement for the Medicare Part D prescription drug benefit and the Medicare Part D annual call letter; general issues related to reform of the Medicare Part D program; and issues related to the Medicare Part B reimbursement of prescription drugs.

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Economics/Economic Development ECN

All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2052 (113th)

Taxation/Internal Revenue Code TAX

Extension of the U.S. R&D tax credit. Issues related to Corporate Tax Reform. Provisions of H.R.2535 and S.1647 "Restoring Access to Medication Act of 2013"

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2535 (113th), S. 1647 (113th)

Health Issues HCR

Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; S.1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of 2013." H.R.1024 and S.557 "Medication Therapy Management Empowerment Act of 2013." General issues related to FDA and NIH funding; Awareness and education about Sanofi's Access to Medicines Program.

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1024 (113th), S. 1871 (113th), S. 557 (113th)

Pharmacy PHA

General issues related to the 340B Federal Drug Pricing Program

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.